The first experience of ex-vivo lung perfusion (EVLP) in Iran: An effective method to increase suitable lung for transplantation

Shafaghi, S. and Najafizadeh, K. and Sheikhy, K. and Aval, Z.A. and Farzanegan, B. and Mafhoomi, Y. and Abdollahi, Z.F. and Emami, H. and Mortaz, E. and Porabdollah, M. and Fard, A.J. and Safaei, M.N. and Slama, A. and Aigner, C. and Hosseini-Baharanchi, F.S. and Dezfuli, A.A. (2016) The first experience of ex-vivo lung perfusion (EVLP) in Iran: An effective method to increase suitable lung for transplantation. International Journal of Organ Transplantation Medicine, 7 (4). pp. 219-227.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: Although lung transplantation is a well-accepted treatment for end-stage lung diseases patients, only 15-20 of the brain-dead donors' lungs are usable for transplantation. This results in high mortality of candidates on waiting lists. Ex-vivo lung perfusion (EVLP) is a novel method for better evaluation of a potential lung for transplantation. Objective: To report the first experience of EVLP in Iran. Methods: The study included a pig in Vienna Medical University, Vienna, Austria, and 4 humans in Masih Daneshvari Hospital, Tehran, Iran. All brain-dead donors from 2013 to 2015 in Tehran were evaluated for EVLP. Donors without signs of severe chest trauma or pneumonia, with poor oxygenation were included. Results: An increasing trend in difference between the pulmonary arterial pO2 and left atrial pO2, an increasing pattern in dynamic lung compliance, and a decreasing trend in the pulmonary vascular resistance, were observed. Conclusion: The initial experience of EVLP in Iran was successful in terms of important/critical parameters. The results emphasize on some important considerations such as precisely following standard lung harvesting and monitoring temperature and pressure. EVLP technique may not be a cost-effective option for low-income countries at first glance. However, because this is the only therapeutic treatment for end-stage lung disease, it is advisable to continue working on this method to find alternatives with lesser costs.

Item Type: Article
Additional Information: cited By 0
Depositing User: eprints admin
Date Deposited: 02 Jul 2018 09:00
Last Modified: 02 Jul 2018 09:00
URI: http://eprints.iums.ac.ir/id/eprint/4504

Actions (login required)

View Item View Item